Fludarabine + Cyclophosphamide + Nirogacestat
Phase 1Terminated 0 watching 0 views this week๐ค Quiet
25
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Multiple Myeloma
Conditions
Relapsed/Refractory Multiple Myeloma
Trial Timeline
Apr 30, 2020 โ Oct 19, 2022
NCT ID
NCT04171843About Fludarabine + Cyclophosphamide + Nirogacestat
Fludarabine + Cyclophosphamide + Nirogacestat is a phase 1 stage product being developed by Precision BioSciences for Relapsed/Refractory Multiple Myeloma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04171843. Target conditions include Relapsed/Refractory Multiple Myeloma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04171843 | Phase 1 | Terminated |
Competing Products
20 competing products in Relapsed/Refractory Multiple Myeloma